Uncategorized

October 12th, 2017

Immunotherapy Active Against Triple-Negative Breast Cancer

By

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), […]

View full entry

Tags: atezolizumab, Breast Cancer, checkpoint inhibitor, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, Tecentriq, Triple Negative Breast Cancer


October 10th, 2017

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

By

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly […]

View full entry

Tags: BRCA breast cancer, Breast Cancer, lynparza, News, olaparib, PARP inhibitor, Precision Cancer Medicine


October 5th, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers

By

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio


October 4th, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq


October 3rd, 2017

New Standard of Care for Treatment of Resectable Gastric Cancer

By

Copyright © 2017 CancerConnect. All Rights Reserved.

View full entry

Tags: Esophageal Cancer, esophago-gastric cancer, Gastric Cancer, News


September 28th, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There remains an unmet need for […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, nivolumab, opdivo, Precision Cancer Medicine, Yervoy


September 25th, 2017

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

By

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, Gastric Cancer, gastro-esophogeal junction cancer, keytruda, metastatic gastric, News, pembrolizumab, Precision Cancer Medicine


September 25th, 2017

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

By

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, Multiple Myeloma, News, PD-1, PD-L1


September 21st, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine


September 20th, 2017

Lower Thyroid Stimulating Hormone Levels Elevate Risk of Thyroid Cancer

By

There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published in American Association for Cancer Research journal examined the effect of Thyroid Stimulating Hormone (TSH) on the development of human papillary thyroid cancer (PTC). […]

View full entry

Tags: News, Thyroid Cancer, Thyroid Stimulating Hormone


September 19th, 2017

Pass it On: It’s Leukemia National Awareness Month

By

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates that 81,080 new cases and 21,270 deaths will occur in the United States in […]

View full entry

Tags: all, AML, CLL, CML, Leukemia, News


September 18th, 2017

Hematopoietic CFC Assays

By mfero mfero

M. Fero 11/20/2011 Materials: BSA in IMDM (100 mg/mL = 10% w/v)  To 5 gm BSA (Sigma, A1933) q.s. to 50 mL with IMDM Rotate at 4ºC for 1 hr. to dissolve. 2.6% Methylcellulose in IMDM (StemCell Technologies #H4100) Add glutamine prior to use Alternatively it can be made as per Appendix 6 (p. 277) […]

View full entry


September 18th, 2017

NSAIDs Decrease Risk of Colorectal Cancer

By

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively relieve pain, inflammation, and fever.  A number of treatment guidelines for osteoarthritis, rheumatoid arthritis, and chronic low back pain recommend the use of NSAIDs […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer


September 18th, 2017

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

By

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, immunotherapy, KEYNOTE-059 programmed death-ligand 1, keytruda, metastatic gastric cancer, News, PD-L1, pembrolizumab, Precision Cancer Medicine, stomach cancer


September 13th, 2017

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths

By

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. Published early online in Cancer, […]

View full entry

Tags: Annual Mammography, Breast Cancer, breast cancer screening, early detection, mammogram, News, Prevents Death from breast cancer